How to use ibrutinib
The emergence of new targeted drugs, affecting B-cell receptor signaling pathway opens a new page in the treatment of chronic lymphocytic leukemia (CLL). It is not simply expanding choice, it will likely to change total strategy of CLL management. Clinical trials have shown improvement of overall su...
Saved in:
| Main Authors: | Е. А. Nikitin, V. I. Vorobiev, М. А. Panteleev, G. E. Gendlin, V. V. Ptushkin |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
ABV-press
2017-04-01
|
| Series: | Онкогематология |
| Subjects: | |
| Online Access: | https://oncohematology.abvpress.ru/ongm/article/view/229 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Rhythm and Conduction Disorders in Patients Receiving Ibrutinib
by: EI Emelina, et al.
Published: (2019-03-01) -
Ibrutinib in the Treatment of Refractory Chronic Lymphocytic Leukemia
by: EA Nikitin, et al.
Published: (2017-07-01) -
Drug review: Ibrutinib
by: Parathan Karunakaran
Published: (2020-01-01) -
Antithrombotic Therapy in Patients with Malignant Lymphoproliferative Disorders Treated with Ibrutinib
by: EI Emelina, et al.
Published: (2019-09-01) -
Real-world cardiovascular risks of ibrutinib in chronic lymphocytic leukemia: a retrospective study
by: Jelena Ivanovic, et al.
Published: (2025-08-01)